Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sunrise Technologies

This article was originally published in The Gray Sheet

Executive Summary

Conditional approval is received from FDA to begin a study of laser thermal keratoplasty for patients with overcorrection (hyperopia) resulting from photorefractive keratectomy or laser in situ keratomileusis (LASIK) treatments for myopia. Enrollment of 10 patients (five post-PRK and five post-LASIK) will begin at the Hunkeler Eye Center at the University of Kansas. The approval is conditioned upon minor changes to the company's study protocol. Sunrise will seek to expand the patient population after one-to-three month follow-up of the initial patient population is complete. The Fremont, California-based company will include data from the study in a premarket approval application, which is slated to be submitted sometime in 1999, for its Corneal Sparing LTK system for the correction of hyperopia, presbyopia and overcorrection resulting from PRK or LASIK

You may also be interested in...

Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar

On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.

Everlywell Raises $175M To Expand Consumer Lab Testing, Digital Health

The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts